Graft Versus Host Disease

Graft Versus Host Disease

Genetic Variants Associated With Inflammatory Bowel Disease and Gut Graft-Versus-Host Disease

Researchers suggest that targeting inflammatory macrophages with recombinant FNDC4 offers an attractive avenue of clinical investigation for management of IBD and gut GVHD.

Blood Advances
Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease

Researchers work to show that BET inhibition by PLX51107 and PLX2853 represents a promising treatment strategy for acute GVHD.

Frontiers in Oncology
γδ T Cells May Aggravate Acute GvHD Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation

The identification of immune cells that correlate with aGVHD is important and intriguing. To date, the involvement of innate-like γδ T cells in the pathogenesis of aGVHD is unclear. 

Frontiers in Immunology

Posttransplant Cyclophosphamide as GVHD Prophylaxis for Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Transplant

Highly promising OS and GRFS rates of 87% and 68%, respectively, were achieved after MMUD-HCT with PTCy.

Blood Advances
Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective

This review summarizes the current literature on the needs and burdens of patients with severe forms of GvHD from a supportive and palliative care perspective.

Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust

This review focuses on the impact of in vivo and ex vivo graft manipulation on immune reconstitution and clinical outcome.

Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease

The transfer of immunomodulatory and immunosuppressive cell populations, including mesenchymal stromal cells and regulatory T-cells, show promising results in GvHD treatment.

HPV32‐Related Heck’s Disease in a Chronic GvHD Patient With Long‐Term Successful KTP Laser Treatment

Study investigators identified and treated a rare case of oral focal epithelial hyperplasia in an adult patient with chronic graft‐vs‐host disease.

Clinical Case Reports
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GvHD

Mesenchymal stem cells represent a promising therapeutic approach for the treatment of GvHD, but so far this strategy has had equivocal clinical efficacy. 

Frontiers in Immunology
Graves’ Disease, a Late Complication of Chronic Graft vs Host Disease

Hyperthyroidism after BMT is thought to occur by GVHD or by donor’s auto-reactive lymphocytes transferred to recipient, with majority of cases occurring with donors that have an underlying...

Journal of the Endocrine Society
Pre-Transplant Rehabilitation to Decrease the Post-Transplant Length of Stay for Hematological Malignancy Patients Undergoing Allo-HSCT

The aim of this study is to investigate the effect of pre-transplant rehabilitation on post-transplant LOS for hematological malignancy patients undergoing allo-HSCT.

Progress in Rehabilitation Medicine
Abatacept May Be Additional Prophylaxis for Graft vs Host Disease in Patients With Beta-Thalassemia

Abatacept added to routine prophylaxis for acute GvHD reduces incidence of severe GvHD at 100 days in children with transfusion-dependent beta-thalassemia.

Hematology Advisor
ROCK2 Inhibitor Belumosudil for Chronic Graft-vs-Host Disease

Jagasia et al find that the oral ROCK2 inhibitor belumosudil produces high response rates and reduced corticosteroid use among patients with chronic GvHD after allogeneic bone marrow...

The ASCO Post
Ruxolitinib Early Administration Reduces Acute GVHD After Alternative Donor Hematopoietic Stem Cell Transplantation in Acute Leukemia

This study aims to observe the safety and clinical efficacy of early application of ruxolitinib to prevent aGVHD after alternative donor transplantation in acute leukemia.

Scientific Reports
Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation

Given before or after transplantation of donor blood or bone marrow cells, bendamustine has been shown to reduce the side effects of the transplant, including GvHD, where the donated cells...

Meibomian Gland Dysfunction in Ocular Graft vs. Host Disease: A Need for Pre-Clinal Models and Deeper Insights

Herein, the current state of the etiology and, pathophysiology of oGvHD based on existing pre-clinical models are reviewed.

International Journal of Molecular Sciences
Ruxolitinib Before Allogeneic Hematopoietic Transplantation in Patients With Myelofibrosis on Behalf SFGM-TC and FIM Groups

This multicenter prospective phase 2 trial analyzes disease-free survival in myelofibrosis patients receiving ruxolitinib for 6 months before transplantation.

Bone Marrow Transplantation
Mesenchymal Stem/Stromal Cells as a Valuable Source for the Treatment of Immune-Mediated Disorders

This paper discusses the therapeutic applications of MSC secretome and its biomedical aspects related to immune-mediated conditions.

Stem Cell Research & Therapy
Interplay Between the Intestinal Microbiota and Acute Graft-Versus-Host Disease: Experimental Evidence and Clinical Significance

The current animal and human studies investigating the intestinal microbiota in aGVHD and the understanding of the influence and management of the microbiota in the clinic are reviewed herein.

Frontiers in Immunology
Profiling Tissue and Biofluid miR-155-5p, miR-155*, and miR-146a-5p Expression in Graft vs Host Disease

In this study, investigators perform comprehensive expression profiling of miR-146a, miR-155, and miR-155* expression in aGvHD target tissue and biofluids and relate expression to post-HSCT outcome

Frontiers in Immunology
GVHD Prophylaxis: Similar Outcomes With PTCy and ATG

A newer regimen is no more effective than an older regimen when both were compared for GVHD prophylaxis in patients who underwent reduced-intensity conditioning followed by a HSCT from...

Shulman Syndrome as a Manifestation of Severe Chronic Graft-versus-Host Disease

Chronic graft-versus-host-disease presenting as EF is a very rare manifestation of cutaneous GVHD.

Journal of Medical Case Reports
FDA Grants Fast Track Designation to Neihulizumab for Acute GVHD

The FDA granted fast track designation to neihulizumab for treatment of steroid-refractory acute graft-versus-host disease, according to the agent’s manufacturer.

Relationship of Donor Age and Relationship to Outcomes of Haploidentical Transplantation With Posttransplant Cyclophosphamide

This study seeks to identify factors to optimize the choice of haplo donors when using posttransplantation cyclophosphamide GVHD prophylaxis.

Blood Advances
Steroid-Dependent Acute GVHD After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Clinical Outcomes

Steroid-sensitive and steroid-dependent acute GvHD groups have similar risks of overall and nonrelapse mortality.

Blood Advances
First-in-Human Phase 1 Trial of Induced Regulatory T Cells for Graft-versus-Host Disease Prophylaxis in HLA-Matched Siblings

Study investigators perform a phase 1, single-center, dose-escalation study to determine the safety profile of iTregs in adults with high-risk malignancy treated with...

Blood Advances
Role of Antithymocyte Globulin in Matched Sibling Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

This study aims to investigate the safety and efficacy of antithymocyte globulin as a standardized part of GVHD prophylaxis in patients receiving MSD -PBSCT.

Human Cytomegalovirus Infection: A Considerable Issue Following Allogeneic Hematopoietic Stem Cell Transplantation

This review summarizes the molecular mechanism and risk factors of HCMV reactivation following allo-HSCT, the diagnosis of CMV infection following allo-HSCT, prophylaxis and treatment...

Oncology Letters
Polymorphisms in CXCR3 Ligands Predict Early CXCL9 Recovery and Severe Chronic GVHD

This study investigates the role of single-nucleotide polymorphisms of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis.

Blood Cancer Journal
Mesenchymal Stem Cell Exosome-Derived miR-223 Alleviates Acute Graft-versus-Host Disease via Reducing the Migration of Donor T Cells

Study investigators perform expression profiling of exosome-miRNAs from human umbilical cord MSCs and murine compact bone MSCs to investigate their immunoregulation effects in aGvHD.

Stem Cell Research & Therapy
The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children

This study aims to evaluate the effectiveness of Ruxolitinib for acute/chronic graft-versus-host disease in children.

Drug Design, Development and Therapy
Efficiency of Human Monocyte-Derived Suppressor Cell-Based Treatment in Graft-versus-Host Disease Prevention While Preserving Graft-versus-Leukemia Effect

The objective of this study is to explore the therapeutic relevance of the HuMoSC in clinical conditions.

Repurposing a Novel Anti-Cancer RXR Agonist to Attenuate Murine Acute GVHD and Maintain Graft-versus-Leukemia Responses

Study investigators have developed a novel pharmacological approach to inhibit graft-versus-host disease by activating retinoid X receptor in donor T cells.


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(235, 64, 52)